This website uses cookies to provide you with the best experience. By using this site you agree to our use of cookies. Please read our cookie notice for more information.

« Back

ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting

July 25, 2018

DUBLIN--(BUSINESS WIRE)-- ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions at the Annual General Meeting of the Company (AGM) held on July 24, 2018 (which resolutions had all been recommended by the Board) were all duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 12, 2018 and are available on the ICON plc website.

The final results of the voting are as follows:

RESOLUTION
NUMBER

  RESOLUTION  

TOTAL
NUMBER OF
VOTES

  VOTE FOR  

VOTE
AGAINST

 

VOTE
WITHHELD

 
           
1.1  

To re-elect Mr. Ciaran Murray

  46,363,577   43,309,546   3,049,154   4,877  
1.2   To re-elect Mr. Declan McKeon   46,363,577   45,438,950   919,871   4,756  
1.3  

To re-elect Mr. Eugene
McCague

  46,363,577   46,158,700   200,090   4,787  
1.4   To re-elect Ms. Joan Garahy   46,363,577   46,160,214   198,360   5,003  
2  

To review the Company's
affairs and consider the
accounts and reports

  46,363,577   46,233,943   1,906   127,728  
3  

To authorise the fixing of the
auditors' remuneration

  46,363,577   43,981,210   2,377,642   4,725  
4  

To authorise the Company to
allot shares

  46,363,577   45,518,647   831,568   13,362  
5**   To disapply pre-emption rights   46,363,577   46,218,055   126,968   18,554  
6**  

To disapply pre-emption rights
for funding capital investment
or acquisitions

  46,363,577   46,159,710   186,608   17,259  
7**  

To authorise the Company to
make market purchases of
shares

  46,363,577   45,717,396   461,062   185,119  
8**  

To authorise the price range at
which the Company can
reissue shares it holds as
treasury shares

  46,363,577   46,253,806   97,134   12,637  

** Special Resolution. All resolutions are ordinary resolutions unless otherwise stated.

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.

ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 93 locations in 37 countries and has approximately 13,650 employees. Further information is available at www.iconplc.com.

Source: ICON plc

All at ICON.

ICON/ICLR-F

 

ICON plc
Investor Relations
1 888 381 7923
or
Brendan Brennan
Chief Financial Officer
+ 353 1 291 2000
Jonathan Curtain
Vice President Corporate Finance and Investor Relations
+1 215 616 3000

Source: ICON plc

 

 

News Provided by Acquire Media



Search Investor